Mechanistic Elucidation of the Antitumor Properties of a Novel Death Receptor 5 Activator
Mengxiong Wang(Stanford University), Brian K. Law(University of Florida Health)
Cited by 3
Related Papers
Rapamycin Disrupts Cyclin/Cyclin-Dependent Kinase/p21/Proliferating Cell Nuclear Antigen Complexes and Cyclin D1 Reverses Rapamycin Action by Stabilizing These Complexes
|Cancer Research|2006|70
CUB domain-containing protein 1 and the epidermal growth factor receptor cooperate to induce cell detachment
|Breast Cancer Research|2016|39
Novel agents that downregulate EGFR, HER2, and HER3 in parallel
|Oncotarget|2015|32